Article
Immunology
Zihan Zhao, Siyang Liu, Rui Sun, Wenjie Zhu, Yulin Zhang, Tianyao Liu, Tianhang Li, Ning Jiang, Hongqian Guo, Rong Yang
Summary: Bladder cancer is a highly malignant tumor with limited improvement in prognosis and survival rates. Immune checkpoint inhibitors have revolutionized the treatment of bladder cancer, but their clinical application is limited by low response rates. This study investigated the combination of oxaliplatin and anti-PD-1 inhibitor in bladder cancer mouse models and found that this combination therapy was more efficient than medication alone.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Junjie Liu, Haisu Tao, Tong Yuan, Jiang Li, Jian Li, Huifang Liang, Zhiyong Huang, Erlei Zhang
Summary: Anti-PD-1/PD-L1 therapy is an effective strategy for cancer treatment, but drug resistance is a challenge. Combining this therapy with regorafenib can enhance its efficacy. Regorafenib modifies the tumor microenvironment through various mechanisms and has immunomodulatory effects on immune cells and tumor cells. Studies on the synergistic mechanism of combination therapy can improve cancer treatment and patient selection.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Alex Frias, Luca Di Leo, Asier Antoranz, Loulieta Nazerai, Marco Carretta, Valerie Bodemeyer, Chiara Pagliuca, Christina Dahl, Giuseppina Claps, Giulio Eugenio Mandelli, Madhavi Dipak Andhari, Maria Pires Pacheco, Thomas Sauter, Caroline Robert, Per Guldberg, Daniel Hargbol Madsen, Francesco Cecconi, Francesca Maria Bosisio, Daniela De Zio
Summary: Loss of Ambra1 in melanoma affects the tumor immune microenvironment (TIME) and the antitumor immune response. It leads to changes in TIME composition and reduces the infiltration of regulatory T cells, resulting in accelerated tumor growth and decreased overall survival. However, loss of Ambra1 also sensitizes melanoma to anti-PD-1 treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Tianqi Liu, Chen Zhu, Xin Chen, Gefei Guan, Cunyi Zou, Shuai Shen, Jianqi Wu, Yuhang Wang, Zhiguo Lin, Ling Chen, Peng Cheng, Wen Cheng, Anhua Wu
Summary: This study reveals the importance of ferroptosis in glioma and proposes a novel immunotherapeutic strategy that combines immune checkpoint blockade treatment with ferroptosis inhibition, showing a synergistic therapeutic effect.
Article
Cell Biology
Depei Li, Wanming Hu, Xiaoping Lin, Ji Zhang, Zhenqiang He, Sheng Zhong, Xia Wen, Peiyu Zhang, Xiaobing Jiang, Hao Duan, Chengcheng Guo, Jian Wang, Jing Zeng, Zhongping Chen, Yonggao Mou, Ke Sai
Summary: This study identified a CARD-associated risk score that divided glioma patients into high- and low-risk subgroups with distinct immune microenvironments and molecular features. The high-risk group exhibited dysfunctional T lymphocytes and an immunosuppressive microenvironment, while the low-risk group showed an immune exclusion genotype. Elevated risk scores were associated with decreased overall survival in IDH-wt gliomas but clinical benefit from checkpoint immunotherapy.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Immunology
Qingyi Wang, Bin Xie, Shuang Liu, Ying Shi, Yongguang Tao, Desheng Xiao, Wenxiang Wang
Summary: The fruitful results of tumor immunotherapy have established its indispensable status in regulating the tumorous immune context. The treatment of programmed cell death receptor 1 (PD-1) blockade is considered one of the most promising approaches for cancer control, with significant efficacy shown in various cancer types. However, more research is needed to understand how anti-PD-1 therapy impacts the immune microenvironment and why some patients develop resistance to PD-1 blockade.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Chemistry, Multidisciplinary
Huihuang Li, Jinbo Chen, Zhenghao Li, Minfeng Chen, Zhenyu Ou, Miao Mo, Ruizhe Wang, Shiyu Tong, Peihua Liu, Zhiyong Cai, Chunyu Zhang, Zhi Liu, Dingshan Deng, Jinhui Liu, Chunliang Cheng, Jiao Hu, Xiongbing Zu
Summary: A systematic multi-omics analysis identified S100A5 as a novel immunosuppressive target for bladder cancer. The expression of S100A5 inhibits CD8(+) T cell recruitment and cytotoxicity, leading to resistance to immune checkpoint blockade therapy. Targeting S100A5 enhances the infiltration and cytotoxicity of CD8(+) T cells, thereby enhancing the efficacy of immune checkpoint blockade therapy in bladder cancer.
Article
Chemistry, Multidisciplinary
Zhiyong Cai, Jinbo Chen, Zhengzheng Yu, Huihuang Li, Zhi Liu, Dingshan Deng, Jinhui Liu, Chunliang Chen, Chunyu Zhang, Zhenyu Ou, Minfeng Chen, Jiao Hu, Xiongbing Zu
Summary: In order to improve the response rate of immune checkpoint blockade monotherapy (ICB), it is important to identify a potential target for combination therapy. Based on the analysis of tumor microenvironment (TME)-related indicators, it is confirmed that BCAT2 plays a role in shaping a noninflamed TME in bladder cancer. Multiomics analysis reveals that BCAT2 inhibits the recruitment of cytotoxic lymphocytes by suppressing proinflammatory cytokine/chemokine-related pathways and the T-cell-chemotaxis pathway. Immunoassays demonstrate a negative correlation between the secretion of CD8(+)T-cell-related chemokines and BCAT2, resulting in a decrease in the number of CD8(+)T cells around BCAT2(+) tumor cells. The combination of BCAT2 deficiency and anti-PD-1 antibody shows a synergistic effect in vivo, suggesting the potential of BCAT2 in combination therapy. Furthermore, the predictive value of BCAT2 in immunotherapy efficacy is validated in multiple immunotherapy cohorts.
Article
Cell Biology
Yuyin Fu, Yujia Peng, Shengyan Zhao, Jun Mou, Lishi Zeng, Xiaohua Jiang, Chengli Yang, Cheng Huang, Yuyan Li, Yin Lu, Mengdan Wu, Yanfang Yang, Ting Kong, Qinhuai Lai, Yangping Wu, Yuqin Yao, Yuxi Wang, Lantu Gou, Jinliang Yang
Summary: The study suggests that a novel combination therapy utilizing both Foretinib and anti-PD-1 antibody has significant therapeutic effects on CRC, improving tumor growth inhibition, tumor regression rates, and overall survival by reshaping the tumor microenvironment and enhancing anti-tumor immunity.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Review
Immunology
Ming Yi, Tianye Li, Mengke Niu, Yuze Wu, Zhenyu Zhao, Kongming Wu
Summary: TGF-beta signaling has predictive value in cancer immunotherapy, and targeted therapies against TGF-beta are important strategies to overcome treatment resistance.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
B. Leticia Rodriguez, Limo Chen, Yanli Li, Shucheng Miao, David H. Peng, Jared J. Fradette, Lixia Diao, Jessica M. Konen, Frank R. Rojas Alvarez, Luisa M. Solis, Xiaohui Yi, Aparna Padhye, Laura A. Gibson, Joshua K. Ochieng, Xiaofei Zhou, Jing Wang, Don L. Gibbons
Summary: The resistance to immune checkpoint blockade (ICB) therapy in non-small cell lung cancer (NSCLC) is associated with infiltrating monocytes, and controlling the differentiation process of monocytes can enhance the therapeutic potential of ICB.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Yang Song, Juan Long, Xiaona Su, Zhuo Chen, Yue He, Weikang Shao, Bin Wang, Chuan Chen
Summary: MSI-H/dMMR has become a crucial biomarker for immune checkpoint inhibitors in advanced colorectal cancer patients, but the proportion of these patients is low. MSS/pMMR patients exhibit poor responses to immunotherapy and there is limited research on immune combination therapy for them. Therefore, studying the mechanism and potential biomarkers of immunotherapy in MSS/pMMR patients is of great importance.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Chemistry, Multidisciplinary
Junlin Li, Yue Yan, Ping Zhang, Junzhou Ding, Yuan Huang, Yun Jin, Lian Li
Summary: The use of (ACCO+CpG)@Gel as a vaccine can establish durable antigen-specific immune memory, improve immune status against orthotopic tumors, and make originally irresponsive tumors responsive to ICB therapy.
JOURNAL OF CONTROLLED RELEASE
(2022)
Article
Oncology
Y. Morera-Diaz, C. Canaan-Haden, J. Sanchez-Ramirez, M. Bequet-Romero, I. Gonzalez-Moya, R. Martinez, V. Falcon, D. Palenzuela, M. Ayala-Avila, J. V. Gavilondo
Summary: This paper reported the development of PKPD-L1(Vac), a new protein vaccine candidate for cancer treatment. The vaccine induced specific immune responses in mice and non-human primates, showing promising preclinical results. It is suggested that the vaccine should move forward to a phase I clinical trial.
Review
Immunology
Ru-Yue Chen, Yun Zhu, Yun-Yan Shen, Qin-Ying Xu, Han-Yun Tang, Ning-Xun Cui, Lu Jiang, Xiao-Mei Dai, Wei-Qing Chen, Qiang Lin, Xiao-Zhong Li
Summary: Programmed cell death 1 receptor (PD-1) and its ligands play a crucial role in immune tolerance, immune homeostasis, and immunosuppression. The PD-1 pathway has been implicated in various diseases, including cancer and autoimmune diseases, and PD-1 blockades have been approved for cancer treatment. This comprehensive review focuses on the structure and expression of PD-1, PD-L1, and PD-L2, the diverse biological functions of PD-1 signaling in health and immune-related diseases, and the immune-related adverse events associated with PD-1 and PD-L1 inhibitors.
FRONTIERS IN IMMUNOLOGY
(2023)
